A carbon monoxide releasing metal organic framework nanoplatform for synergistic treatment of triple-negative breast tumors

• Published in: Journal of nanobiotechnology Vol. 20; no. 1; pp. 494 - 13
• Main Authors: Cong, Yiyang, Sun, Bo, Hu, Jianlun, Li, Xiaoyang, Wang, Yanan, Zhang, Jingyi, Yang, Dongzhi, Lu, Weifei, Ding, Zhi, Wang, Xiaofeng, Hong, Hao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.11.2022; BioMed Central; BMC
• Subjects: Breast cancer; Cancer; Carbon Dioxide; Carbon Monoxide; Catalysis; Cobalt; Controllability; Coordination compounds; Health aspects; Humans; Hypoxia; Imaging; Irradiation; Ligands; Light irradiation; Metal-organic frameworks; Metal-Organic Frameworks - chemistry; Metal-Organic Frameworks - pharmacology; Metal–organic framework; Microscopy; Nanomedicine; Notch1 protein; Peptides; Polyacrylic acid; Polyethylene glycol; Polyethylene terephthalate; Positron emission tomography; Radiation; Ruthenium; Ruthenium - chemistry; Ruthenium - pharmacology; Signaling; Synergistic therapy; Therapeutics, Experimental; Tirapazamine; Tissues; Triple Negative Breast Neoplasms - drug therapy; Tumor cells; Tumor Microenvironment; Tumors; Zirconium; Zirconium isotopes; China; Metal–organic framework; Carbon monoxide; Catalysis; Imaging; Synergistic therapy
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-022-01704-2

Carbon monoxide (CO) is an important signaling molecule participating in multiple biological functions. Previous studies have confirmed the valuable roles of CO in cancer therapies. If the CO concentration and distribution can be controlled in tumors, new cancer therapeutic strategy may be developed to benefit the patient survival. In this study, a UiO-67 type metal-organic framework (MOF) nanoplatform was produced with cobalt and ruthenium ions incorporated into its structure (Co/Ru-UiO-67). Co/Ru-UiO-67 had a size range of 70-90 nm and maintained the porous structure, with cobalt and ruthenium distributed uniformly inside. Co/Ru-UiO-67 was able to catalyze carbon dioxide into CO upon light irradiation in an efficient manner with a catalysis speed of 5.6 nmol/min per 1 mg Co/Ru-UiO-67. Due to abnormal metabolic properties of tumor cells, tumor microenvironment usually contains abundant amount of CO . Co/Ru-UiO-67 can transform tumor CO into CO at both cellular level and living tissues, which consequently interacts with relevant signaling pathways (e.g. Notch-1, MMPs etc.) to adjust tumor microenvironment. With proper PEGylation (pyrene-polyacrylic acid-polyethylene glycol, Py-PAA-PEG) and attachment of a tumor-homing peptide (F3), functionalized Co/Ru-UiO-67 could accumulate strongly in triple-negative MDA-MB-231 breast tumors, witnessed by positron emission tomography (PET) imaging after the addition of radioactive zirconium-89 ( Zr) into Co-UiO-67. When applied in vivo, Co/Ru-UiO-67 could alter the local hypoxic condition of MDA-MB-231 tumors, and work synergistically with tirapazamine (TPZ). This nanoscale UiO-67 MOF platform can further our understanding of CO functions while produce CO in a controllable manner during cancer therapeutic administration.